{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Robert", "organization": "", "rank": 1, "lastname": "CYRAN"}], "original": "By ROBERT CYRAN"}, "news_desk": "Business", "slideshow_credits": null, "abstract": null, "multimedia": [], "headline": {"kicker": "Breakingviews", "content_kicker": "Breakingviews", "main": "Johnson &amp; Johnson Is Urged to Slim Down"}, "print_page": null, "keywords": [{"value": "Eli Lilly and Company", "is_major": "N", "rank": "1", "name": "organizations"}, {"value": "Johnson & Johnson", "is_major": "N", "rank": "2", "name": "organizations"}, {"value": "Abbott Laboratories", "is_major": "N", "rank": "3", "name": "organizations"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "Medical Devices", "is_major": "N", "rank": "5", "name": "subject"}], "snippet": "The health care giant is criticized by many investors for its mediocre shareholder returns and its lack of merger-and-acquisition activity.", "source": "The New York Times", "lead_paragraph": "The health care giant is criticized by many investors for its mediocre shareholder returns and its lack of merger-and-acquisition activity.", "word_count": "388", "pub_date": "2016-06-03T00:00:00Z", "subsection_name": "DealBook", "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/06/03/business/dealbook/johnson-johnson-is-urged-to-slim-down.html", "_id": "57509af838f0d86ce33330ac"}